Covered recipient · General Payments record
KEVIN D CANNON
Allopathic & Osteopathic Physicians Hospitalist
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$116.03
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $116.03 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.33 | 1 |
| Corcept Therapeutics | $24.70 | 1 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KEVIN D CANNON
NPI 1700897022 · CMS profile ID 122867
Allopathic & Osteopathic Physicians / Hospitalist
WILMINGTON, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1700897022?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700897022?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700897022?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1700897022?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $116.03 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.33 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200194185 | CMS |
| Corcept Therapeutics | $24.70 | 01/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214243214 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,200.00 | 1 |
| PY2025 | Principal investigator | $6,407,903.58 | 738 |
| PY2024 | Recipient | $12,299.41 | 13 |
| PY2024 | Principal investigator | $7,058,469.69 | 390 |
| PY2023 | Recipient | $3,980.00 | 2 |
| PY2023 | Principal investigator | $7,125,617.33 | 899 |
| PY2022 | Recipient | $9,082.00 | 12 |
| PY2022 | Principal investigator | $6,929,547.49 | 979 |
| PY2021 | Recipient | $14,312.20 | 61 |
| PY2021 | Principal investigator | $9,361,495.59 | 2,459 |
| PY2020 | Recipient | $233.41 | 1 |
| PY2020 | Principal investigator | $5,812,787.31 | 750 |
| PY2019 | Principal investigator | $4,820,055.08 | 826 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
403 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $164.40 | 12/31/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130968908 |
| Recipient | PFIZER INC. | $3,200.00 | 12/30/2024 | Covered Recipient Physician | NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1130898013 |
| Principal investigator 1 | ModernaTX, Inc. | $399,477.62 | 12/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147191506 |
| Principal investigator 1 | ModernaTX, Inc. | $119,433.22 | 12/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191516 |
| Principal investigator 1 | ModernaTX, Inc. | $200,730.60 | 12/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191510 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,484.05 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449818 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,713.75 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449858 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449892 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $578.36 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449894 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,238.25 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449926 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,282.85 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449958 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,409.73 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082450024 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,299.48 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082450028 |
| Principal investigator 1 | ModernaTX, Inc. | $75.13 | 12/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191498 |
| Principal investigator 1 | BioNTech SE | $4,948.00 | 12/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665549 |
| Principal investigator 1 | PFIZER INC. | $3,464.76 | 12/10/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130968732 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 12/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082447896 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,050.00 | 12/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082447918 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 12/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082447942 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,500.00 | 12/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082447944 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,206.55 | 12/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082447994 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,083.94 | 12/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082448028 |
| Principal investigator 1 | PFIZER INC. | $1,665.65 | 12/05/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1130968914 |
| Principal investigator 1 | BioNTech SE | $96.00 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665555 |
| Principal investigator 1 | BioNTech SE | $3,000.00 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665563 |
| Principal investigator 1 | BioNTech SE | $3,324.00 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665578 |
| Principal investigator 1 | ModernaTX, Inc. | $75.13 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191496 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31,206.06 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082446660 |
| Principal investigator 1 | Novo Nordisk AS | $4,812.50 | 12/02/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096793705 |
| Principal investigator 1 | ModernaTX, Inc. | $47,329.10 | 11/27/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191484 |
| Principal investigator 1 | BioNTech SE | $954.00 | 11/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665559 |
| Principal investigator 1 | ModernaTX, Inc. | $88.79 | 11/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191482 |
| Recipient | PFIZER INC. | $3,200.00 | 11/26/2024 | Covered Recipient Physician | NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1130899325 |
| Principal investigator 1 | PFIZER INC. | $4,908.41 | 11/26/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130983628 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $23,909.72 | 11/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445870 |
| Principal investigator 1 | ModernaTX, Inc. | $81.96 | 11/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191480 |
| Principal investigator 1 | PFIZER INC. | $816.34 | 11/21/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1130983125 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,041.00 | 11/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445394 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,500.00 | 11/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445424 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 11/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445446 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,422.00 | 11/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445472 |
| Principal investigator 1 | Novo Nordisk AS | $1,529.24 | 11/20/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096761871 |
| Principal investigator 1 | BioNTech SE | $95.90 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665545 |
| Principal investigator 1 | BioNTech SE | $12,926.00 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665567 |
| Principal investigator 1 | BioNTech SE | $97.27 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665593 |
| Principal investigator 1 | ModernaTX, Inc. | $88.79 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191478 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26,772.26 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445106 |
| Principal investigator 1 | ModernaTX, Inc. | $81.96 | 11/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191476 |
| Principal investigator 1 | PFIZER INC. | $34,226.55 | 11/13/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1130982584 |
| Principal investigator 1 | PFIZER INC. | $3,353.90 | 11/13/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1130983131 |
| Principal investigator 1 | PFIZER INC. | $4,000.00 | 11/13/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1130983615 |
| Principal investigator 1 | BioNTech SE | $6,218.00 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665576 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,680.25 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444158 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26,514.00 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444170 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $784.08 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444182 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $778.95 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444188 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,104.00 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444200 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35,078.95 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444252 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.31 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444272 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $490.05 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444300 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,017.00 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444302 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,601.00 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444316 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,905.00 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444336 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,710.00 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444346 |
| Principal investigator 1 | PFIZER INC. | $2,456.77 | 11/08/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130983119 |
| Principal investigator 1 | BioNTech SE | $10,922.00 | 11/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665571 |
| Principal investigator 1 | PFIZER INC. | $666.64 | 11/05/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130983622 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $295,501.75 | 11/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082443658 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,000.00 | 10/31/2024 | Non-covered Recipient Entity ACCELLACARE | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity | No dispute reported | 06/30/2026 | 1110845189 |
| Principal investigator 1 | ModernaTX, Inc. | $204.90 | 10/31/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191466 |
| Principal investigator 1 | BioNTech SE | $132.00 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665541 |
| Principal investigator 1 | BioNTech SE | $7,263.00 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665543 |
| Principal investigator 1 | BioNTech SE | $284.65 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665551 |
| Principal investigator 1 | BioNTech SE | $522.42 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665588 |
| Principal investigator 1 | BioNTech SE | $4,255.00 | 10/22/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665547 |
| Principal investigator 1 | PFIZER INC. | $73,035.00 | 10/22/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1130992715 |
| Principal investigator 1 | ModernaTX, Inc. | $249.45 | 10/16/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147191468 |
| Principal investigator 1 | Novo Nordisk AS | $21,397.45 | 10/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097093769 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 10/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097609670 |
| Principal investigator 1 | BioNTech SE | $13,195.00 | 10/15/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665557 |
| Principal investigator 1 | ModernaTX, Inc. | $399.12 | 10/14/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191464 |
| Principal investigator 1 | BioNTech SE | $15,992.00 | 10/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665584 |
| Principal investigator 1 | BioNTech SE | $234.42 | 10/09/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665553 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 10/05/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 | No dispute reported | 06/30/2026 | 1130983424 |
| Principal investigator 1 | PFIZER INC. | $16,877.38 | 10/05/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130992861 |
| Principal investigator 1 | BioNTech SE | $600.00 | 10/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665561 |
| Principal investigator 1 | BioNTech SE | $5,461.00 | 10/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665565 |
| Principal investigator 1 | BioNTech SE | $11,158.00 | 10/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665582 |
| Recipient | PFIZER INC. | $620.00 | 09/29/2024 | Covered Recipient Physician | NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1130898359 |
| Principal investigator 1 | PFIZER INC. | $875.00 | 09/25/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1131016033 |
| Principal investigator 1 | BioNTech SE | $3,285.00 | 09/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665507 |
| Principal investigator 1 | Novo Nordisk AS | $2,080.19 | 09/20/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096869509 |
| Principal investigator 1 | Novo Nordisk AS | $400.00 | 09/20/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097893229 |
| Principal investigator 1 | BioNTech SE | $693.00 | 09/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665505 |
| Principal investigator 1 | BioNTech SE | $96.00 | 09/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665527 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $433,682.84 | 09/18/2024 | Non-covered Recipient Entity Pmg Research | phase III efficacy for obesity - with T2DM | No dispute reported | 06/30/2026 | 1101071833 |
| Principal investigator 1 | PFIZER INC. | $35,914.86 | 09/11/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131016027 |
| Principal investigator 1 | BioNTech SE | $9,300.00 | 09/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665515 |
| Principal investigator 1 | PFIZER INC. | $4,333.50 | 09/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1131018498 |
| Principal investigator 1 | BioNTech SE | $5,184.00 | 09/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665499 |
| Principal investigator 1 | ModernaTX, Inc. | $598.68 | 08/29/2024 | Non-covered Recipient Entity ACCELLACARE RESEARCH WILMINGTON | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147180899 |
| Principal investigator 1 | PFIZER INC. | $38,854.00 | 08/28/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1131031876 |
| Principal investigator 1 | PFIZER INC. | $26,001.00 | 08/28/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1131032490 |
| Principal investigator 1 | BioNTech SE | $5,461.00 | 08/27/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665539 |
| Recipient | PFIZER INC. | $3,200.00 | 08/27/2024 | Covered Recipient Physician | RSV VACCINE PROT SUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1130898009 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 08/27/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE | No dispute reported | 06/30/2026 | 1131031870 |
| Principal investigator 1 | Novo Nordisk AS | $10,113.04 | 08/23/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096808138 |
| Principal investigator 1 | PFIZER INC. | $679.79 | 08/23/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131033138 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 08/21/2024 | Non-covered Recipient Entity PMG RES OF WILMINGTON, LLC | NN9535-4984 | No dispute reported | 06/30/2026 | 1096863476 |
| Principal investigator 1 | PFIZER INC. | $9,350.25 | 08/21/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131033133 |
| Principal investigator 1 | BioNTech SE | $10,506.00 | 08/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665497 |
| Principal investigator 1 | Novo Nordisk AS | $6,080.40 | 08/19/2024 | Non-covered Recipient Entity PMG RES OF WILMINGTON, LLC | NN9535-4984 | No dispute reported | 06/30/2026 | 1096857743 |
| Principal investigator 1 | PFIZER INC. | $5,000.00 | 08/16/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE | No dispute reported | 06/30/2026 | 1131033747 |
| Principal investigator 1 | PFIZER INC. | $2,039.37 | 08/14/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131031882 |
| Principal investigator 1 | PFIZER INC. | $156,840.49 | 08/14/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131033393 |
| Principal investigator 1 | PFIZER INC. | $645.00 | 08/14/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1131033565 |
| Principal investigator 1 | PFIZER INC. | $25,381.50 | 08/14/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131033571 |
| Principal investigator 1 | BioNTech SE | $5,184.00 | 08/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665501 |
| Principal investigator 1 | BioNTech SE | $66.00 | 08/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665529 |
| Principal investigator 1 | BioNTech SE | $3,285.00 | 08/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665495 |
| Principal investigator 1 | BioNTech SE | $385.00 | 08/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665503 |
| Principal investigator 1 | BioNTech SE | $396.00 | 08/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665511 |
| Principal investigator 1 | BioNTech SE | $96.00 | 08/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665523 |
| Principal investigator 1 | BioNTech SE | $66.00 | 08/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665535 |
| Principal investigator 1 | PFIZER INC. | $76,476.35 | 08/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1131032998 |
| Principal investigator 1 | PFIZER INC. | $34,544.63 | 08/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131033387 |
| Principal investigator 1 | PFIZER INC. | $63,787.50 | 08/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1131033739 |
| Principal investigator 1 | BioNTech SE | $4,352.00 | 08/01/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665519 |
| Principal investigator 1 | BioNTech SE | $3,465.00 | 08/01/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665531 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $15.10 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082393398 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $44.50 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082393400 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $60.40 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082393402 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $233.63 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082393404 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $305.89 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082393406 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $32.57 | 07/25/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082393394 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $128.98 | 07/25/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082393396 |
| Principal investigator 1 | BioNTech SE | $15,295.00 | 07/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665493 |
| Principal investigator 1 | Novo Nordisk AS | $300.00 | 07/22/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096855643 |
| Principal investigator 1 | Novo Nordisk AS | $7,580.45 | 07/22/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096856586 |
| Principal investigator 1 | Novavax Inc | $25,680.00 | 07/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) | No dispute reported | 06/30/2026 | 1123376635 |
| Principal investigator 1 | PFIZER INC. | $2,073.60 | 07/18/2024 | Non-covered Recipient Entity Accellacare | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1130916779 |
| Principal investigator 1 | PFIZER INC. | $2,454.45 | 07/17/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 | No dispute reported | 06/30/2026 | 1130991879 |
| Principal investigator 1 | PFIZER INC. | $11,727.50 | 07/17/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131042444 |
| Principal investigator 1 | BioNTech SE | $5,738.00 | 07/16/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665533 |
| Principal investigator 1 | PFIZER INC. | $5,637.79 | 07/16/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131043296 |
| Principal investigator 1 | PFIZER INC. | $82,485.00 | 07/16/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1131043302 |
| Principal investigator 1 | PFIZER INC. | $9,760.00 | 07/16/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE | No dispute reported | 06/30/2026 | 1131043391 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $928.34 | 07/16/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082393392 |
| Principal investigator 1 | BioNTech SE | $11,754.00 | 07/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665491 |
| Principal investigator 1 | BioNTech SE | $110.97 | 07/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665509 |
| Principal investigator 1 | BioNTech SE | $132.00 | 07/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665513 |
| Principal investigator 1 | BioNTech SE | $600.00 | 07/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665517 |
| Principal investigator 1 | BioNTech SE | $474.42 | 07/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665521 |
| Principal investigator 1 | BioNTech SE | $2,387.00 | 07/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665525 |
| Principal investigator 1 | PFIZER INC. | $4,893.75 | 07/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1131042648 |
| Principal investigator 1 | BioNTech SE | $5,045.00 | 07/02/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665537 |
| Principal investigator 1 | Novo Nordisk AS | $7.27 | 07/02/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096760307 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,706.80 | 06/28/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 2 STUDY TO ASSESS THE VIROLOGIC EFFICACY OF REGN10933+REGN10987 ACROSS DIFFERENT DOSE REGIMENS IN OUTPATIENTS WITH SARS-COV-2 INFECTION | No dispute reported | 06/30/2026 | 1082430524 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $53,395.94 | 06/26/2024 | Non-covered Recipient Entity Pmg Research | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 1101070517 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/26/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096730360 |
| Principal investigator 1 | Novo Nordisk AS | $7.27 | 06/26/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096799701 |
| Principal investigator 1 | PFIZER INC. | $866.11 | 06/26/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131065349 |
| Principal investigator 1 | BioNTech SE | $18,344.00 | 06/25/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665451 |
| Principal investigator 1 | Novo Nordisk AS | $1,245.99 | 06/21/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096741088 |
| Principal investigator 1 | Novo Nordisk AS | $343.90 | 06/21/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097940129 |
| Principal investigator 1 | ModernaTX, Inc. | $71.55 | 06/20/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147191460 |
| Principal investigator 1 | BioNTech SE | $22,866.00 | 06/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665467 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/14/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096745004 |
| Principal investigator 1 | Novo Nordisk AS | $7.27 | 06/14/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096833028 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/14/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096885576 |
| Principal investigator 1 | BioNTech SE | $66.00 | 06/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665439 |
| Principal investigator 1 | BioNTech SE | $20,583.00 | 06/11/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665459 |
| Principal investigator 1 | Novavax Inc | $20,038.00 | 06/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) | No dispute reported | 06/30/2026 | 1123378283 |
| Principal investigator 1 | Novo Nordisk AS | $3,765.64 | 06/10/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 1096882181 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,136.00 | 06/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | No dispute reported | 06/30/2026 | 1079007604 |
| Principal investigator 1 | BioNTech SE | $1,500.00 | 06/06/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665469 |
| Principal investigator 1 | BioNTech SE | $9,234.00 | 06/06/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665479 |
| Principal investigator 1 | PFIZER INC. | $176,836.80 | 06/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131059421 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/05/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096834196 |
| Principal investigator 1 | PFIZER INC. | $2,133.00 | 06/05/2024 | Non-covered Recipient Entity Accellacare Wilmington | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1130917571 |
| Principal investigator 1 | PFIZER INC. | $5,116.30 | 06/05/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131066535 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/04/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096771184 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,154.50 | 06/03/2024 | Non-covered Recipient Entity Accellacare-Wilmington | Phase III efficacy for obesity - without T2DM | No dispute reported | 06/30/2026 | 1138418633 |
| Principal investigator 1 | PFIZER INC. | $398.94 | 06/01/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131066205 |
| Principal investigator 1 | Novo Nordisk AS | $600.00 | 05/31/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 1096866856 |
| Principal investigator 1 | ModernaTX, Inc. | $1,250.00 | 05/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147191458 |
| Principal investigator 1 | Novo Nordisk AS | $4,629.48 | 05/29/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096871466 |
| Principal investigator 1 | Novo Nordisk AS | $18,224.89 | 05/29/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098188746 |
| Principal investigator 1 | PFIZER INC. | $491,059.38 | 05/29/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131074320 |
| Principal investigator 1 | BioNTech SE | $17,843.00 | 05/28/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665485 |
| Principal investigator 1 | Novo Nordisk AS | $1,250.00 | 05/24/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 1096751859 |
| Principal investigator 1 | Novo Nordisk AS | $1,512.50 | 05/24/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 1096757159 |
| Principal investigator 1 | PFIZER INC. | $72,948.10 | 05/24/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131074986 |
| Principal investigator 1 | BioNTech SE | $930.00 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665427 |
| Principal investigator 1 | BioNTech SE | $396.00 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665433 |
| Principal investigator 1 | BioNTech SE | $393.39 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665435 |
| Principal investigator 1 | BioNTech SE | $336.00 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665445 |
| Principal investigator 1 | BioNTech SE | $1,604.15 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665453 |
| Principal investigator 1 | BioNTech SE | $66.00 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665455 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147191456 |
| Principal investigator 1 | Novo Nordisk AS | $335.79 | 05/23/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096884773 |
| Principal investigator 1 | BioNTech SE | $9,418.00 | 05/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665429 |
| Principal investigator 1 | BioNTech SE | $71,591.00 | 05/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665465 |
| Principal investigator 1 | BioNTech SE | $14,484.00 | 05/14/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665447 |
| Principal investigator 1 | BioNTech SE | $8,049.00 | 05/14/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665483 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $289,554.90 | 05/13/2024 | Non-covered Recipient Entity Pmg Research | Phase III efficacy for obesity - without T2DM | No dispute reported | 06/30/2026 | 1101070895 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 05/13/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096761816 |
| Principal investigator 1 | Novo Nordisk AS | $2,019.64 | 05/10/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 1096820037 |
| Recipient | PFIZER INC. | $330.00 | 05/07/2024 | Covered Recipient Physician | BNT162 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1130898362 |
| Principal investigator 1 | PFIZER INC. | $1,178.73 | 05/04/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131074589 |
| Principal investigator 1 | PFIZER INC. | $9,250.00 | 05/04/2024 | Non-covered Recipient Entity Accellacare US Inc | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131074980 |
| Principal investigator 1 | Novo Nordisk AS | $2,831.27 | 04/30/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096846313 |
| Principal investigator 1 | Novo Nordisk AS | $17,828.46 | 04/30/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097852279 |
| Principal investigator 1 | PFIZER INC. | $4,675.00 | 04/30/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY | No dispute reported | 06/30/2026 | 1131088995 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,568.00 | 04/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | No dispute reported | 06/30/2026 | 1079007596 |
| Principal investigator 1 | PFIZER INC. | $1,196.82 | 04/26/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131087546 |
| Principal investigator 1 | ModernaTX, Inc. | $1,278.00 | 04/25/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147191454 |
| Principal investigator 1 | BioNTech SE | $300.00 | 04/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665473 |
| Principal investigator 1 | BioNTech SE | $17,883.00 | 04/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665487 |
| Principal investigator 1 | PFIZER INC. | $3,853.35 | 04/19/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE | No dispute reported | 06/30/2026 | 1131089557 |
| Principal investigator 1 | BioNTech SE | $19,691.00 | 04/16/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665431 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/15/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096762285 |
| Principal investigator 1 | BioNTech SE | $750.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665441 |
| Principal investigator 1 | BioNTech SE | $750.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665443 |
| Principal investigator 1 | BioNTech SE | $25,072.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665449 |
| Principal investigator 1 | BioNTech SE | $924.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665457 |
| Principal investigator 1 | BioNTech SE | $66.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665461 |
| Principal investigator 1 | BioNTech SE | $750.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665463 |
| Principal investigator 1 | BioNTech SE | $132.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665471 |
| Principal investigator 1 | BioNTech SE | $900.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665475 |
| Principal investigator 1 | BioNTech SE | $300.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665477 |
| Principal investigator 1 | BioNTech SE | $600.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665481 |
| Principal investigator 1 | BioNTech SE | $300.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665489 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/12/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096814102 |
| Principal investigator 1 | PFIZER INC. | $322.85 | 04/10/2024 | Non-covered Recipient Entity Accellacare Wilmington | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131018504 |
| Principal investigator 1 | PFIZER INC. | $916.50 | 04/05/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131087714 |
| Principal investigator 1 | PFIZER INC. | $4,770.36 | 04/05/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE | No dispute reported | 06/30/2026 | 1131089563 |
| Principal investigator 1 | PFIZER INC. | $13,998.48 | 04/05/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131089569 |
| Principal investigator 1 | BioNTech SE | $6,864.00 | 04/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665437 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/02/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096837615 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,488.00 | 04/01/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | No dispute reported | 06/30/2026 | 1079007600 |
| Principal investigator 1 | PFIZER INC. | $63,757.68 | 03/30/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131074425 |
| Principal investigator 1 | PFIZER INC. | $19,826.60 | 03/29/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131077816 |
| Principal investigator 1 | PFIZER INC. | $11,665.40 | 03/28/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131104093 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/27/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096797399 |
| Principal investigator 1 | Novo Nordisk AS | $400.00 | 03/27/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098215174 |
| Principal investigator 1 | Novo Nordisk AS | $5,487.10 | 03/27/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098239113 |
| Principal investigator 1 | PFIZER INC. | $5,020.23 | 03/27/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131104099 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,112.00 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662576 |
| Principal investigator 1 | Bavarian Nordic A/S | $5,920.00 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662586 |
| Principal investigator 1 | Bavarian Nordic A/S | $102,169.00 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662592 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,960.00 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662594 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,096.00 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662612 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,000.00 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662622 |
| Principal investigator 1 | Bavarian Nordic A/S | $7,456.00 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662624 |
| Principal investigator 1 | BioNTech SE | $10,686.00 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665397 |
| Principal investigator 1 | PFIZER INC. | $9,374.32 | 03/26/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131077252 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/25/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096770598 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 03/22/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131074829 |
| Principal investigator 1 | ModernaTX, Inc. | $387,434.47 | 03/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147191452 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33,412.22 | 03/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | No dispute reported | 06/30/2026 | 1082421341 |
| Principal investigator 1 | Bavarian Nordic A/S | $16,280.00 | 03/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662584 |
| Principal investigator 1 | Bavarian Nordic A/S | $24,904.00 | 03/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662610 |
| Principal investigator 1 | Bavarian Nordic A/S | $20,504.00 | 03/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662620 |
| Principal investigator 1 | Bavarian Nordic A/S | $17,088.00 | 03/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662632 |
| Principal investigator 1 | BioNTech SE | $8,444.00 | 03/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665379 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/15/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096839624 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/15/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096840761 |
| Principal investigator 1 | Bavarian Nordic A/S | $160.00 | 03/14/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662608 |
| Principal investigator 1 | PFIZER INC. | $8,348.13 | 03/14/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE | No dispute reported | 06/30/2026 | 1131104384 |
| Principal investigator 1 | Bavarian Nordic A/S | $22,243.00 | 03/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662604 |
| Principal investigator 1 | BioNTech SE | $21,948.00 | 03/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665419 |
| Principal investigator 1 | PFIZER INC. | $19,500.00 | 03/12/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1131104420 |
| Principal investigator 1 | PFIZER INC. | $50,597.09 | 03/08/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131104159 |
| Principal investigator 1 | Bavarian Nordic A/S | $80.00 | 03/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662602 |
| Principal investigator 1 | BioNTech SE | $9,927.00 | 03/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665413 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/06/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096808610 |
| Principal investigator 1 | Novo Nordisk AS | $800.00 | 03/06/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 1096811003 |
| Principal investigator 1 | PFIZER INC. | $816.52 | 03/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 | No dispute reported | 06/30/2026 | 1130991872 |
| Principal investigator 1 | PFIZER INC. | $16,700.84 | 03/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131073499 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/05/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096871499 |
| Principal investigator 1 | PFIZER INC. | $105.50 | 03/05/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY | No dispute reported | 06/30/2026 | 1131074325 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,376.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662578 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,660.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662588 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,057.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662598 |
| Principal investigator 1 | Bavarian Nordic A/S | $5,735.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662600 |
| Principal investigator 1 | Bavarian Nordic A/S | $40.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662614 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,220.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662616 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,448.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662618 |
| Principal investigator 1 | Bavarian Nordic A/S | $970.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662626 |
| Principal investigator 1 | Bavarian Nordic A/S | $8,388.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662628 |
| Principal investigator 1 | Bavarian Nordic A/S | $13,536.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662634 |
| Principal investigator 1 | Bavarian Nordic A/S | $94.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662636 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,032.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662638 |
| Principal investigator 1 | Bavarian Nordic A/S | $94.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662918 |
| Principal investigator 1 | Bavarian Nordic A/S | $530.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662920 |
| Principal investigator 1 | BioNTech SE | $11,843.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665421 |
| Principal investigator 1 | Novo Nordisk AS | $4,534.70 | 02/29/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096790072 |
| Principal investigator 1 | PFIZER INC. | $32,507.50 | 02/29/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 1131074431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $895,609.33 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | No dispute reported | 06/30/2026 | 1082419061 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $140,284.13 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | No dispute reported | 06/30/2026 | 1082419105 |
| Principal investigator 1 | Bavarian Nordic A/S | $39,656.00 | 02/27/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662596 |
| Principal investigator 1 | PFIZER INC. | $37,343.20 | 02/27/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131104508 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,157.00 | 02/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | No dispute reported | 06/30/2026 | 1079007598 |
| Principal investigator 1 | PFIZER INC. | $73,939.87 | 02/24/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131074331 |
| Principal investigator 1 | Novo Nordisk AS | $24,809.91 | 02/23/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097547174 |
| Principal investigator 1 | Novo Nordisk AS | $1,600.00 | 02/23/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098153663 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 02/23/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131074841 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 02/22/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147191450 |
| Principal investigator 1 | BioNTech SE | $693.00 | 02/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665391 |
| Principal investigator 1 | PFIZER INC. | $17,827.00 | 02/21/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 1131077822 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,458.70 | 02/20/2024 | Non-covered Recipient Entity Accellacare-Wilmington | Phase III efficacy for obesity - without T2DM | No dispute reported | 06/30/2026 | 1101070897 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,585.00 | 02/19/2024 | Non-covered Recipient Entity Accellacare-Wilmington | phase III efficacy for obesity - with T2DM | No dispute reported | 06/30/2026 | 1101071835 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 02/16/2024 | Non-covered Recipient Entity ACCELLACARE | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1131093569 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 02/16/2024 | Non-covered Recipient Entity ACCELLACARE | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1131093610 |
| Principal investigator 1 | PFIZER INC. | $540.00 | 02/16/2024 | Non-covered Recipient Entity ACCELLACARE | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1131093856 |
| Principal investigator 1 | PFIZER INC. | $425.00 | 02/16/2024 | Non-covered Recipient Entity ACCELLACARE | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1131093861 |
| Principal investigator 1 | PFIZER INC. | $6,300.00 | 02/16/2024 | Non-covered Recipient Entity ACCELLACARE | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1131093946 |
| Principal investigator 1 | PFIZER INC. | $12,354.50 | 02/16/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1131104745 |
| Principal investigator 1 | Bavarian Nordic A/S | $371.00 | 02/15/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662574 |
| Principal investigator 1 | Bavarian Nordic A/S | $371.00 | 02/15/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662922 |
| Principal investigator 1 | PFIZER INC. | $11,394.29 | 02/14/2024 | Non-covered Recipient Entity Accellacare US Inc | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131104455 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 02/14/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE | No dispute reported | 06/30/2026 | 1131104514 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,775.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662580 |
| Principal investigator 1 | Bavarian Nordic A/S | $80.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662606 |
| Principal investigator 1 | Bavarian Nordic A/S | $8,836.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662630 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,200.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662640 |
| Principal investigator 1 | Bavarian Nordic A/S | $7,500.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662646 |
| Principal investigator 1 | BioNTech SE | $937.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665393 |
| Principal investigator 1 | BioNTech SE | $1,380.84 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665415 |
| Principal investigator 1 | BioNTech SE | $300.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665417 |
| Principal investigator 1 | PFIZER INC. | $11,320.00 | 02/13/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131104153 |
| Principal investigator 1 | Novo Nordisk AS | $7.27 | 02/09/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096811503 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/09/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096873851 |
| Principal investigator 1 | PFIZER INC. | $24,100.00 | 02/08/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 1131073530 |
| Principal investigator 1 | PFIZER INC. | $7,768.79 | 02/08/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY | No dispute reported | 06/30/2026 | 1131074490 |
| Principal investigator 1 | BioNTech SE | $1,874.00 | 02/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665385 |
| Principal investigator 1 | PFIZER INC. | $11,041.60 | 02/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131077247 |
| Principal investigator 1 | PFIZER INC. | $362.37 | 02/01/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY | No dispute reported | 06/30/2026 | 1131074788 |
| Principal investigator 1 | BioNTech SE | $937.00 | 01/31/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665399 |
| Principal investigator 1 | PFIZER INC. | $5,450.00 | 01/31/2024 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131073493 |
| Principal investigator 1 | Janssen Research & Development, LLC | $55,804.00 | 01/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | No dispute reported | 06/30/2026 | 1079007602 |
| Principal investigator 1 | Novo Nordisk AS | $2,217.68 | 01/29/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 1096740583 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $150.00 | 01/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | AN OPEN-LABEL MULTI-CENTRE ENABLING STUDY TO EVALUATE INFLUENZA LIKE I | No dispute reported | 06/30/2026 | 1127528172 |
| Principal investigator 1 | PFIZER INC. | $25,522.75 | 01/26/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131074835 |
| Principal investigator 1 | PFIZER INC. | $1,400.00 | 01/26/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE | No dispute reported | 06/30/2026 | 1131110188 |
| Principal investigator 1 | ModernaTX, Inc. | $200.00 | 01/25/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147191448 |
| Principal investigator 1 | PFIZER INC. | $2,718.20 | 01/25/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE | No dispute reported | 06/30/2026 | 1131107899 |
| Principal investigator 1 | Novo Nordisk AS | $962.17 | 01/24/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096750754 |
| Principal investigator 1 | Novo Nordisk AS | $4,837.50 | 01/24/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096858290 |
| Principal investigator 1 | Novo Nordisk AS | $14,911.39 | 01/24/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097991874 |
| Principal investigator 1 | Bavarian Nordic A/S | $347.00 | 01/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662582 |
| Principal investigator 1 | Bavarian Nordic A/S | $20,295.00 | 01/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662590 |
| Principal investigator 1 | Bavarian Nordic A/S | $14,905.38 | 01/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662642 |
| Principal investigator 1 | Bavarian Nordic A/S | $94.62 | 01/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662644 |
| Principal investigator 1 | BioNTech SE | $1,386.00 | 01/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665381 |
| Principal investigator 1 | PFIZER INC. | $16,494.80 | 01/20/2024 | Non-covered Recipient Entity Accellacare US Inc | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131109773 |
| Principal investigator 1 | PFIZER INC. | $276.74 | 01/17/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 | No dispute reported | 06/30/2026 | 1130991806 |
| Principal investigator 1 | BioNTech SE | $2,811.00 | 01/16/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665383 |
| Principal investigator 1 | Novo Nordisk AS | $116.16 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097076165 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097094806 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097308863 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097325896 |
| Principal investigator 1 | Novo Nordisk AS | $116.16 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097342530 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097369037 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097550795 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097608573 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097727247 |
| Principal investigator 1 | Novo Nordisk AS | $116.16 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097887682 |
| Principal investigator 1 | Novo Nordisk AS | $116.16 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097909084 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097934371 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1097971582 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098002442 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098092797 |
| Principal investigator 1 | Novo Nordisk AS | $116.16 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098113122 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098193164 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098201736 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098201810 |
| Principal investigator 1 | Novo Nordisk AS | $352.20 | 01/16/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4954 | No dispute reported | 06/30/2026 | 1098231556 |
| Principal investigator 1 | Novo Nordisk AS | $7.27 | 01/15/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096802074 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 01/15/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096874474 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $38,926.80 | 01/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | AN OPEN-LABEL MULTI-CENTRE ENABLING STUDY TO EVALUATE INFLUENZA LIKE I | No dispute reported | 06/30/2026 | 1127551092 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 01/12/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096718969 |
| Principal investigator 1 | Novo Nordisk AS | $7.27 | 01/12/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096808813 |
| Principal investigator 1 | PFIZER INC. | $5,891.00 | 01/11/2024 | Non-covered Recipient Entity Accellacare US Inc | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131107031 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,846.05 | 01/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA | No dispute reported | 06/30/2026 | 1127528174 |
| Principal investigator 1 | BioNTech SE | $693.00 | 01/09/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665387 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $72,172.98 | 01/09/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 1/2, RANDOMIZED, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALU | No dispute reported | 06/30/2026 | 1127515818 |
| Principal investigator 1 | PFIZER INC. | $5,045.98 | 01/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131076617 |
| Principal investigator 1 | BioNTech SE | $675.35 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665389 |
| Principal investigator 1 | BioNTech SE | $488.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665395 |
| Principal investigator 1 | BioNTech SE | $600.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665401 |
| Principal investigator 1 | BioNTech SE | $2,618.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665403 |
| Principal investigator 1 | BioNTech SE | $300.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665405 |
| Principal investigator 1 | BioNTech SE | $750.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665407 |
| Principal investigator 1 | BioNTech SE | $300.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665409 |
| Principal investigator 1 | BioNTech SE | $6,000.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665411 |
| Principal investigator 1 | BioNTech SE | $600.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665423 |
| Principal investigator 1 | BioNTech SE | $240.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150665425 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | AN OPEN-LABEL MULTI-CENTRE ENABLING STUDY TO EVALUATE INFLUENZA LIKE I | No dispute reported | 06/30/2026 | 1127522856 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 01/02/2024 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 1096848664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,741.89 | 01/01/2024 | Non-covered Recipient Entity Accellacare-Wilmington | phase III efficacy for obesity - with T2DM | No dispute reported | 06/30/2026 | 1101067879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,031.18 | 01/01/2024 | Non-covered Recipient Entity Accellacare-Wilmington | Phase III efficacy for obesity - without T2DM | No dispute reported | 06/30/2026 | 1101068913 |